Phase 2 Radiotherapy trials recruiting now

All Radiotherapy trials, every phase

Other phases for Radiotherapy

Phase 2 Radiotherapy trials

• A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
  NCT07239466 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer
  NCT06765616 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
  NCT06768307 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
  NCT07646639 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
  NCT06356584 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
  NCT07071103 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
  NCT06923345 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
  NCT06958419 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
  NCT06958432 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
  NCT07284992 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
  NCT04636008 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
  NCT07058948 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy
  NCT06201078 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
  NCT07742332 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
  NCT07038304 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
  NCT06262321 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
  NCT06758830 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
  NCT07100600 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
  NCT06249321 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.